![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Alibaba
BABA
Broadcom
AVGO
Disney
DIS
Meta Platforms
META
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
TCRX TScan Therapeutics
- 2.610
- +0.050+1.95%
Trading Jan 24 12:17 ET
147.48MMarket Cap-2.75P/E (TTM)
2.610High2.490Low55.78KVolume2.600Open2.560Pre Close142.13KTurnover0.16%Turnover RatioLossP/E (Static)56.51MShares9.69052wk High0.64P/B92.44MFloat Cap2.30552wk Low--Dividend TTM35.42MShs Float14.710Historical High--Div YieldTTM4.69%Amplitude1.450Historical Low2.547Avg Price1Lot Size
TScan Therapeutics Stock Forum
Sign in to post a comment
$TScan Therapeutics (TCRX.US)$ Press Release: TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
Dow Jones· 1 min ago
Dow Jones· 1 min ago
1
$TScan Therapeutics (TCRX.US)$ TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting
Benzinga· 1 min ago
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is high...
Benzinga· 1 min ago
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is high...
$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...
$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
Benzinga· 2 mins ago
Benzinga· 2 mins ago
$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Inc - on-Track to Report Initial Data From Solid Tumor Clinical Trial in 2024
1
$TScan Therapeutics (TCRX.US)$
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
1
$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
1
2
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Trytosaveabit OP : TScan Therapeutics Enters Securities Purchase Agreement With Lynx1 Capital, Investment Fund Advised By Lynx1 For Sale Of $30M Of Pre-funded Warrants To Buy Up To Aggregate Of 7.50M Shares Of Voting Common Stock At $4.00 Per Pre-funded Warrant